Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Anthony Jarkowski III, PharmD, BCOP
Authored Items
Ipilimumab: Unique Responses, Toxicities, and Recommendations for the Use of the First Anti–CTLA-4 Therapy in Patients with Melanoma
Michael K.K. Wong, MD, PhD, FRCPC
,
Anthony Jarkowski III, PharmD, BCOP
JHOP - March 2013 VOL 3, NO 1
in
Drug Profiles/Updates
The Risk of Neurotoxicity with Concomitant Use of Aprepitant and Ifosfamide
Anthony Jarkowski III, PharmD, BCOP
,
Austin Miller, PhD
,
Tammy A. Hecke, RN, BSN
,
Leona Blustein, PharmD
,
Michael K.K. Wong, MD, PhD, FRCPC
JHOP - June 2011, Vol 1, No 2
in
Original Article
Last modified: November 11, 2019